NuCana is trading 8.3% lower at $1.00, with no clear company-specific catalyst identified.
- Shares fell 6.84% to $1.09 in the October 2 regular session.
- The latest reported news was a September 30 announcement that Europe granted a composition-of-matter patent for cancer candidate NUC-7738; that news does not clearly explain the current decline.
- Broader indices were higher, offering no clear market-direction explanation.